Faster Fracture Fixation in Anticoagulated Patients:
5 Data-Driven Recommendations

Fracture care is often a race against time. In orthopedic trauma, the interval between injury and fixation directly influences survival, recovery, and long-term mobility. Yet for the growing population of patients taking anticoagulants, this race can be complicated, especially when it comes to balancing surgical urgency with hemostatic safety. From hip and femur fractures to pelvic trauma, anticoagulation can delay surgery and increase perioperative risk if not managed proactively.

Here are 5 evidence-based best practices for managing anticoagulated fracture patients, from admission to operation.

1: Assess Early
Roughly one in five patients presenting with femur fractures are taking anticoagulants such as warfarin or a direct oral anticoagulant (DOAC).¹ This prevalence is even higher among older adults with atrial fibrillation, venous thromboembolism, or mechanical heart valves, the same population most prone to fragility fractures.^2-5 Because these agents alter perioperative bleeding risk, identifying anticoagulation status and INR assessment during the initial evaluation is critical to avoiding preventable delays and complications.⁵

Once anticoagulant use is confirmed, it’s important to initiate reversal protocols promptly rather than waiting until the surgical case is scheduled. Hospitals that implement standardized anticoagulation alerts or reversal protocols consistently achieve faster surgical readiness, which can lead to lower mortality rates.^6-8

Clinical takeaway: Begin anticoagulant reversal planning upon admission once anticoagulant use is identified, not after surgical scheduling.

2: Timing Is Tissue
Timely surgical intervention for fractures is both an operational goal and a determinant of the patient’s overall outcome. The AAOS and Advanced Trauma Life Support (ATLS) guidelines recommend performing hip fracture surgery within 24 to 48 hours of admission, even in anticoagulated patients.⁹ Multiple studies confirm that exceeding this window increases the risk of 30-day mortality, extends hospital length of stay, and delays postoperative ambulation and rehabilitation.^8,10-13

To meet this critical window, INR assessment and reversal should proceed concurrently with surgical preparation. Waiting for laboratory clearance before alerting the operating room only prolongs treatment. Institutions that streamline these processes demonstrate significant reductions in door-to-incision times and improved inpatient outcomes.

Clinical takeaway: Replace the mindset of “delay until safe” with “make safe quickly.” Prompt reversal enables timely surgery without compromising patient safety.

3: Rapid Reversal Requires the Right Agent
The choice of anticoagulant reversal method can determine whether surgery happens within the guideline-recommended window or after it. For fracture patients on anticoagulants, every hour between diagnosis and surgery carries weight. A timely reversal can mean same-day surgery, while a delay in surgery may result in higher morbidity, transfusion requirements, and prolonged hospitalization.^6-8

Plasma continues to be one of the most commonly used vitamin K antagonist (VKA) reversal; however, it’s not the quickest.¹⁴ In a pivotal multicenter trial involving urgent surgical patients, those receiving 4-factor prothrombin complex concentrate (PCC) achieved an INR below 1.5 within 30 minutes, compared with 6 to 12 hours for plasma. This time advantage directly influenced surgical readiness, with the 4-factor PCC group proceeding to the operating room a median of five hours earlier.¹⁵

4-factor PCC provides a rapid, efficient means of restoring coagulation, achieving therapeutic factor levels with significantly less infusion volume than plasma. This concentrated formulation is especially advantageous for patients with cardiac or renal comorbidities, who run the risk of fluid overload with plasma.^16,17 When used for warfarin reversal, 4-factor PCC administered alongside intravenous vitamin K delivers swift and sustained correction of coagulation, normalizing the INR within minutes rather than hours.¹⁵ Compared with plasma, this approach shortens time to surgical readiness and reduces the risk of fluid overload in critical patients.

Clinical takeaway: 4-factor PCC is a safe and faster alternative to plasma for urgent VKA reversal.

4: Translation into Real-World Emergency Care
The American College of Emergency Physicians (ACEP) multidisciplinary expert panel places 4-factor PCC  plus intravenous vitamin K in its Tier-1 recommendations for urgent warfarin reversal when patients have a life-threatening bleed or critical-site bleed, or require emergency surgery or urgent invasive procedures.¹⁸ This is reinforced by other major societies across high-stakes scenarios. In intracranial hemorrhage, the Neurocritical Care Society/Society of Critical Care Medicine guideline recommends PCC over plasma for VKA reversal to achieve faster INR correction and limit hematoma expansion.¹⁹

However, translating evidence-based anticoagulation reversal into daily practice requires a well-defined, multidisciplinary protocol that activates seamlessly from the emergency department to the operating room. A clinical decision tool or standardized protocol that integrates the latest evidence-based recommendations, emphasizes the importance of emergency supportive measures, facilitates risk stratification for patients who may benefit, and delineates which interventions are most or least likely to confer benefit would be considerably valuable.

Clinical takeaway: For urgent warfarin reversal in life-threatening or critical-site bleeding, guidelines recommend 4-factor PCC plus IV vitamin K as first-line therapy supported by standardized, multidisciplinary protocols to ensure rapid, evidence-based care.

5: Restarting Anticoagulant Therapy
The CHEST 2022 guideline emphasizes that for patients on a VKA undergoing surgery or a procedure, clinicians should avoid routine bridging with heparin or low-molecular-weight heparin (LMWH), except in patients with high risk of thromboembolism. Generally, the guidelines prioritize early resumption of the patient’s VKA once adequate hemostasis is achieved. After the procedure, warfarin should typically be restarted within 24 hours for most patients, assuming bleeding risk is controlled, rather than extending the anticoagulation interruption or automatically initiating therapeutic LMWH.²⁰

Bridging therapy is reserved only for patients at very high thromboembolic risk (for example, recent venous thromboembolism or mechanical heart valve with high stroke risk) and who are at low risk of bleeding. This strategy enables resuming antithrombotic protection while minimizing bleeding complications associated with intensive bridging regimens.²⁰

Clinical takeaway: Resume anticoagulation only after secure hemostasis, progressing from prophylaxis to full therapy as risk declines.

Reducing Delays and Improving Outcomes
Early identification of anticoagulant use and activation of standardized reversal protocols with efficient and recommended reversal agents allow surgical teams to meet the evidence-based goal of fracture repair within 24 to 48 hours of admission.⁹ Rapid reversal strategies not only shorten time to incision but also reduce overall mortality.^6-8,15  Postoperatively, structured anticoagulation resumption guided by thrombotic and bleeding risk ensures continued safety beyond the operating room.²⁰ By embedding these principles into trauma workflows and fostering collaboration among emergency medicine, anesthesia, pharmacy, and orthopedic surgery, hospitals can transform anticoagulated fracture care into a model of coordinated, evidence-based efficiency, where every hour saved translates into improved outcomes and faster recovery.

References

1. Farhan-Alanie MM, Eardley WGP. The management of anticoagulated fragility femoral fracture patients. Hip Int. 2024;34(6):772–781. doi:10.1177/11207000241282303
2. Sherer JA, Huang Q, Kiel DP, Benjamin EJ, Trinquart L. Atrial Fibrillation and the Risk of Subsequent Fracture. Am J Med. 2020;133(8):954–960. doi:10.1016/j.amjmed.2020.02.012
3. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med. 2006;166(2):241–6. doi:10.1001/archinte.166.2.241
4. Mack CA, Lau C, Girardi LN. There is still no alternative to warfarin for mechanical valves: It remains the most effective anticoagulant. J Thorac Cardiovasc Surg. 2025;170(2):489–494. doi:10.1016/j.jtcvs.2024.07.011
5. Sachdev D, Khalil L, Gendi K, et al. Perioperative management of traditional and direct oral anticoagulants in hip fracture patients. Orthop Rev (Pavia). 2024;16:115605. doi:10.52965/001c.115605
6. Ahmed I, Khan MA, Nayak V, Mohsen A. An evidence-based warfarin management protocol reduces surgical delay in hip fracture patients. J Orthop Traumatol. 2014;15(1):21–7. doi:10.1007/s10195-013-0274-7
7. You D, Xu Y, Krzyzaniak H, Korley R, Carrier M, Schneider P. Safety of expedited-surgery protocols in anticoagulant-treated patients with hip fracture: a systematic review and meta-analysis. Can J Surg. 2023;66(2):E170–E180. doi:10.1503/cjs.010021
8.  Pincus D, Ravi B, Wasserstein D, et al. Association Between Wait Time and 30-Day Mortality in Adults Undergoing Hip Fracture Surgery. JAMA. 2017;318(20):1994–2003. doi:10.1001/jama.2017.17606
9. American Academy of Orthopaedic Surgeons. Management of hip fractures in older adults. Accessed October 8, 2025. https://www.aaos.org/globalassets/quality-and-practice-resources/hip-fractures-in-the-elderly/hipfxcpg.pdf.
10. Vitale MA, Vanbeek C, Spivack JH, Cheng B, Geller JA. Pharmacologic reversal of warfarin-associated coagulopathy in geriatric patients with hip fractures: a retrospective study of thromboembolic events, postoperative complications, and time to surgery. Geriatr Orthop Surg Rehabil. 2011;2(4):128–34. doi:10.1177/2151458511417434
11. Ashouri F, Al-Jundi W, Patel A, Mangwani J. Management of warfarin anticoagulation in patients with fractured neck of femur. ISRN Hematol. 2011;2011:294628. doi:10.5402/2011/294628
12. Murphy JR, Loh J, Smith NC, Stone NC. Association of length of hospital stay with delay to surgical fixation of hip fracture. Can J Surg. 2022;65(2):E188–E192. doi:10.1503/cjs.017520
13. Ogawa T, Aoki T, Shirasawa S. Effect of hip fracture surgery within 24 hours on short-term mobility. J Orthop Sci. 2019;24(3):469–473. doi:10.1016/j.jos.2018.11.001
14. Refaai MA, Goldstein JN. Four-Factor Prothrombin Complex Concentrate vs Plasma in Patients on Vitamin K Antagonists With Gastrointestinal Bleeding or Needing a Gastrointestinal Procedure: A Retrospective Analysis of 2 Randomized Controlled Trials. J Am Coll Emerg Physicians Open. 2025;6(3):100142. doi:10.1016/j.acepjo.2025.100142
15. Goldstein JN, Refaai MA, Milling TJ, Jr., et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–87. doi:10.1016/S0140-6736(14)61685-8
16. Refaai MA, Goldstein JN, Lee ML, Durn BL, Milling TJ, Jr., Sarode R. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. Transfusion. 2015;55(11):2722–9. doi:10.1111/trf.13191
17. Quinlan DJ, Eikelboom JW, Weitz JI. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation. 2013;128(11):1179–81. doi:10.1161/CIRCULATIONAHA.113.005107
18. Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. Ann Emerg Med. 2020;76(4):470–485. doi:10.1016/j.annemergmed.2019.09.001
19. Frontera JA, Lewin JJ, 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6–46. doi:10.1007/s12028-015-0222-x
20. Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207–e243. doi:10.1016/j.chest.2022.07.025